San Francisco - Accumulating evidence suggests new biologic agents may be used with potential benefit in the management of dermatomyositis, pyoderma gangrenosum, bullous diseases, cutaneous sarcoidosis, and severe atopic dermatitis.Dermatologists, however, have also been looking to use various older therapies in new ways to treat these disabling diseases, Jeffrey P. Callen, M.D., said.
FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.